Skip redundant pieces
School of Medicine
Department of Urology

 
Basic Science/Laboratory Clinical Research

Finding the cure for urologic disease remains one of the Department of Urology at the University of Kansas Medical Center’s top priorities. Cutting edge research is the reason why the nationally renowned urologists at University of Kansas Medical Center can provide hope to patients that are trying to look for answers. Our department continues to expand our research activities and opportunities. Just in the last 3 years, we have attracted world renowned researchers in the field of prostate cancer to expand our research interests both in the laboratory as well as in the clinic. We work extensively with the Kansas Masonic Cancer Center to offer the latest study protocols to our patients and to invest in our basic scientists who are trying to find a cure for cancer.

The University of Kansas Medical Center is also renowned for the study of male reproductive health and male contraception development. The Department of Urology is working closely with basic scientists in this filed to understand the causes of unexplained male infertility and to find treatments for men with this problem.

Through a combination of basic science research and clinical studies, our department strives to engage in research which will make a difference in the lives of our patients. Our researchers are some of the leaders in the prevention, early detection, and cure of urologic disease, and have published numerous peer-reviewed scientific papers in their areas of expertise.

We only participate in ethical medical research that we genuinely believe will benefit our patients. The health and safety of our patients is our highest priority. Participation in clinical studies is entirely voluntary and detailed informed consent is mandatory.

Clinical Trials

  1. Griebling TL (PI):  Prospective, Multicenter, Randomized, Parallel-Group Trial, Comparing the Safety and Efficacy of InterStim® Therapy to Standard Medical Therapy for Subjects with Symptoms of Overactive Bladder (Medtronic InSite UI protocol #1634 and Medtronic InSite UF protocol #1635).  Sponsor: Medtronic, Inc.  2007-present.  Study open to enrollment.
  1. Griebling TL (PI):  A 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder.  Sponsor: Pfizer, Inc.  2009-present.  Study open to enrollment.
  1. Griebling TL (PI):  A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects with Interstitial Cystitis / Painful Bladder Syndrome.  Sponsor: Johnson & Johnson Pharmaceutical Research & Development, LLC.  2010-present.  Study open to enrollment.